Bourse falls on Friday as a pullback in gold sends miners tumbling; reports Kevin Warhs tipped as next Fed boss weighs on $A; Nine acquires QMS for $850m; ResMed beats consensus. Follow live.

Neutral editorial coverage examining institutional commentary, healthcare sector context, and index association surrounding a respiratory medical technology provider within established United States ...

Pulsed-field ablation, transcatheter heart valves, and IVL are among the top stories, as they drive growth among the largest ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $279.86, with a ...

Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and ...

Resmed (NYSE: RMD) shares ticked up before hours today on second-quarter results that came in ahead of the consensus forecast ...

ASX slips 0.7% as late pullback drags gold shares lower on Fed chair speculation; bullion drops ~5% amid rate-hike fears.

U.S. President Donald Trump said he has selected Kevin Warsh to be the next Federal Reserve chair.

Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP ...

ResMed founder Dr. Peter Farrell has received the Horatio Alger Award, recognizing his contributions to respiratory care and ...

The table inside ranks the 20 biggest percentage winners and losers among stocks in the ASX300 at the end of each trading day ...

Resmed has beaten expectations with $2 billion in second-quarter revenue and says weight loss drugs are actually boosting sales, rather than hurting them.